<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="132723">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01784978</url>
  </required_header>
  <id_info>
    <org_study_id>SUNRISES STUDY (CRAD001LIC34T)</org_study_id>
    <nct_id>NCT01784978</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancer</brief_title>
  <acronym>SUNRISES</acronym>
  <official_title>Randomized ph. II Study to Explore Efficacy and Feasibility of Upfront Rotations Between SUNitinib and Everolimus vs Sequential Treatment of 1st lIne Sunitinib &amp; 2nd Line EverolimuS Until Progression in Pats Met. Clear Cell Renal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Associació per a la Recerca Oncologica, Spain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pivotal S.L.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Associació per a la Recerca Oncologica, Spain</source>
  <oversight_info>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>Germany: Ministry of Health</authority>
    <authority>Greece: Ministry of Health and Welfare</authority>
    <authority>Italy: National Monitoring Centre for Clinical Trials - Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the progression-free survival, of patients who
      receive rotations of sunitinib and everolimus versus patients who receive sunitinib as a
      first line treatment followed by everolimus when progression occurs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, randomized phase II study to investigate the feasibility of
      alternating cycles of treatment with sunitinib and everolimus compared to sequential
      treatment of sunitinib followed by everolimus.

      The study population consists of adult patients (over 18 years old) with clear cell mRCC
      (Metastatic Renal Cell Cancer) who have not received prior therapy for their metastatic
      disease.

      The purpose of the study is to determine the progression free survival, feasibility and
      safety profile of the experimental arm compared to standard of care.

      In the experimental arm alternating treatment will consist of repeating cycles of 24 weeks
      of treatment consisting of 12 weeks of sunitinib 4weeks on 2 weeks off, 50 mg pd followed by
      12 weeks of everolimus 10 mg per day 11 weeks on 1 week off in patients with metastatic
      clear cell renal cancer. The comparative arm will be the standard regimen of sunitinib (50
      mg pd 4/2) until progression, followed thereafter by everolimus (10 mg per day continuously,
      11/1) until progression.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression-free survival (PFS) rate 1 year</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS of rotational arm versus PFS of the 2 lines in control arm</measure>
    <time_frame>From date of randomization until the date of first documented progression assesed up to 30 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From the date of the tratment start to the date of death or the last contact for alived patients at the momment of data censored. Assesed up to 30 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Profile</measure>
    <time_frame>From the first treatment dose until 28 days after study treatment discontinuation. Assesed up to 30 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective tumor response rate per arm</measure>
    <time_frame>From the date of first tumor response to the date of progression or start date of other cancer therapy. Assesed up to 30 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">115</enrollment>
  <condition>Metastatic Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Rotational arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alternating cycles of treatment with sunitinib and everolimus; repeating cycles of 24 weeks of treatment consisting of 12 weeks of sunitinib 4weeks on 2 weeks off, 50 mg pd followed by 12 weeks of everolimus 10 mg per day 11 weeks on 1 week off in patients with metastatic clear cell renal cancer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequential arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The comparative arm will be the standard regimen of sunitinib (50 mg pd 4/2) until progression, followed thereafter by everolimus (10 mg per day continuously, 11/1) until progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sunitinib</intervention_name>
    <description>50 mg pd</description>
    <arm_group_label>Rotational arm</arm_group_label>
    <arm_group_label>Sequential arm</arm_group_label>
    <other_name>SUTENT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>10 mg pd</description>
    <arm_group_label>Rotational arm</arm_group_label>
    <arm_group_label>Sequential arm</arm_group_label>
    <other_name>AFINITOR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Renal cell carcinoma with a predominant clear cell component confirmed by histology.

          -  Advanced disease: metastatic AND, not suitable for resection

          -  Male or female, aged 18 years or older

          -  ECOG (Eastern Cooperative Oncology Group) Performance Status of 0 or 1

          -  Low or intermediate MSKCC (Memorial Sloan Kettering Cancer Center) prognostic risk
             score,i.e. no more than 2 of the following:

               -  Karnofsky performance status (&lt;80%)

               -  Low serum hemoglobin (≤ 13 g/dL for males and ≤ 11.5 g/dL for females)

               -  High corrected serum calcium (≥ 10 mg/dL)

          -  Target and/or non-target lesions according to RECIST 1.1 ( Response Evaluation
             Criteria in Solid Tumors)

          -  Expected survival of at least 3 months.

          -  No prior systemic treatment. But adjuvant treatment is ok if stopped from ≥ 24 months

          -  Adequate bone marrow function as shown by:

          -  Adequate liver function as shown by:

          -  Adequate renal function as shown by serum creatinine ≤ 1.5 x ULN (upper limit of
             normal)

          -  Left ventricular ejection fraction ≥55% on gated cardiac blood pool scan, or normal
             left ventricular function and fractional shortening on echocardiogram (according to
             institutional limits).

          -  SBP (systolic blood pressure) ≤140mmHg and DBP (diastolic blood pressure)

               -  90mmHg (it is acceptable to initiate antihypertensive treatment prior to
                  registration to achieve these goals).

          -  Able to commence treatment within 7 days of registration.

          -  Willing and able to comply with follow-up and all other protocol requirements.

          -  Written informed consent

        Exclusion Criteria:

          -  Prior treatment with VEGF-targeting agents or multi-kinase inhibitors or
             mTOR-targeting agents

          -  Active central nervous system metastases.

          -  Other malignancy diagnosed within the last 5 years, except the following if
             adequately treated: superficial squamous cell carcinoma or basal cell carcinoma of
             skin, superficial bladder cancer (T1 and G1 or T1 and G2), stage 1 cervical cancer.

          -  Treatment with an investigational agent in the last 4 w.

          -  Known to be HIV positive.

          -  Evidence of chronic hepatitis due to hepatitis B virus (HBV) or hepatitis C virus
             (HCV)

          -  Clinically significant heart disease (NYHA Class III or IV)

          -  History of hypertension requiring hospitalization.

          -  Other serious illnesses,

          -  Immunotherapy or chemotherapy in the last 4 w (6 weeks for nitrosoureas)

          -  Major surgery in the last 4 w, or planned in the next 6 w

          -  Radiation therapy in the last 2 w, or planned in the next 6 w

          -  NCI CTCAE (Common Toxicity Criteria for Adverse Effects) version 4.0 grade 3 or worse
             hemorrhage in last 4 w.

          -  Any of the following in the last year: myocardial infarction, severe/unstable angina,
             coronary/peripheral artery bypass graft, symptomatic congestive heart failure,
             cerebrovascular accident or transient ischemic attack, or pulmonary embolism.

          -  Pre-existing thyroid abnormality with thyroid function that cannot be maintained in
             the normal range with medication.

          -  Ongoing cardiac dysrhythmias of NCI CTCAE version 4.0 grade ≥2, atrial fibrillation
             of any grade, or prolongation of the corrected QT interval (QTc) to &gt;450 msec for
             males or &gt;470 msec for females

          -  Uncontrolled diabetes as defined by fasting serum glucose &gt;1.5 X ULN.

          -  Pregnancy,lactation. Inadequate contraception.

          -  Known allergy or hypersensitivity to everolimus, sunitinib or iodine.

          -  Medical or psychiatric condition that compromises the patient's ability to give
             informed consent.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joaquim Bellmunt, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associacio Per la Recerca Oncológica (APRO)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joaquim Bellmunt, MD/PhD</last_name>
    <phone>+34 93 2483137</phone>
    <email>jbellmunt@parcdesalutmar.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Inmaculada Musté</last_name>
    <phone>+34 93 2483137</phone>
    <email>oncologia.apro@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hopital Bordeaux University</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alain Ravaud, MD/PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linnel Geoffrois, MD</last_name>
      <phone>(0)3 83 59 84 61</phone>
      <email>l.geoffrois@nancy.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Linnel Geoffrois, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ALEXANDRA General Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Aristotelis Bamias, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Euromedical General Klinik</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Konstantinos Papazisis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;San Donato&quot;</name>
      <address>
        <city>Arezzo</city>
        <zip>52100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sergio Bracarda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>A Coruña</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Urbano Anido, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Emilio Esteban, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marta López-Brea, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Joaquim Bellmunt, MD/PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Daniel Castellano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>José Luis González Larriba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clara Campal. Hospital Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Emiliano Calvo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Enrique Grande, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jose Angel Arranz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Maria Isabel Sáez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Cristina Hernando, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 26, 2014</lastchanged_date>
  <firstreceived_date>December 11, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>renal</keyword>
  <keyword>metastatic</keyword>
  <keyword>clear</keyword>
  <keyword>cell</keyword>
  <keyword>Sunitinib</keyword>
  <keyword>Everolimus</keyword>
  <keyword>Alternating</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
